IJMSRT foster a global community of researchers and provide them with a platform to publish and access high-quality scientific content. We strive to be at the forefront of scientific communication, enabling the rapid dissemination of cutting-edge research and driving advancements in various fields.
Read moreAbstract Background: Proton pump inhibitors (PPIs), including pantoprazole and omeprazole, are commonly used to treat acidrelated disorders. Gastrointestinal symptoms may occur during treatment, but patient-reported symptoms do not necessarily establish an adverse drug reaction. Methods: This cross-sectional observational community survey included 100 adults from Bengaluru, comprising 50 physical proformas and 50 digital responses. The sample included 74 pantoprazole users and 26 omeprazole users. Demographic information, medicine use and reported gastrointestinal symptoms were summarized using descriptive frequencies and percentages. The dissertation also recorded global spontaneous-reporting counts for selected gastrointestinal events from WHO VigiAccess. Results: New or suspected gastrointestinal discomfort was recorded in 27.0% of pantoprazole users and 23.1% of omeprazole users. In the pantoprazole group, the dissertation’s symptom summary recorded abdominal pain/cramping (9.5%), bloating/gas/flatulence (6.8%), diarrhoea/loose stools (6.8%) and nausea (1.4%). In the omeprazole group, bloating/gas/flatulence and diarrhoea/loose stools were each recorded in 7.7%, nausea in 3.8%, and abdominal pain was not recorded. The VigiAccess extraction log listed 24,546 gastrointestinal disorder reports for pantoprazole and 38,702 for omeprazole. Conclusion: Symptoms were reported in both groups, but the descriptive design, unequal group sizes and absence of diagnostic testing do not establish causality, statistical significance or comparative risk. VigiAccess report counts are not incidence rates.
REFERENCES
[1]. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
[2]. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2017.
[3]. Katzung BG, Trevor AJ. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2018.
[4]. DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V. Pharmacotherapy: A Pathophysiologic Approach. 11th ed. New York: McGraw-Hill Education; 2020.
[5]. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2019.
[6]. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-28.
[7]. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-20.
[8]. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-80.
[9]. Sharma PK, Ahuja V, Madan K, Gupta S, Raizada A, Sharma MP. Prevalence, severity, and risk factors of symptomatic gastroesophageal reflux disease among employees of a large hospital in Northern India. Indian J Gastroenterol. 2011;30(3):128-34.
[10]. Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51(8):751-67.
[11]. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528-34.
[12]. Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A comprehensive review. Gut Liver. 2017;11(1):27-37.
[13]. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther. 1995;9(4):363-78.
[14]. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)- isomer of omeprazole. Clin Pharmacokinet. 2001;40(6):411-26.
[15]. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29(9):769-84. doi:10.2165/00002018-200629090-00002.
[16]. Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201-11. doi:10.1007/s40264-014-0144-0.
[17]. Scarpignato C, Gatta L, Zullo A, Blandizzi C; Sige-Tigo-Aigo Working Group. Effective and safe proton pump inhibitor therapy in acid-related diseases: a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.
[18]. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2-3.
[19]. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5(4):219-32.
[20]. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19-24.
[21]. Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27-36.
[22]. Imhann F, Bonder MJ, Vila AV, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-8. doi:10.1136/gutjnl-2015-310376.
[23]. Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34(4):771-85. doi:10.1016/j.cll.2014.08.008.
[24]. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-90.
[25]. Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, et al. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol. 2019;25(22):2706-19.
[26]. Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Margolis KJ, Marks A, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749-56. doi:10.1136/gutjnl-2015-310861.
[27]. Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2(1):42.
[28]. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504-8.
[29]. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11-12):1269-81.
[30]. Janarthanan S, Ditah I, Adler DG, Mutha P. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001-10.
[31]. Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, Johansen C, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100(9):1503-7.
[32]. Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182-96. [33]. Jaynes M, Kumar AB. The2019;10:2042098618809927.
[34]. Haastrup P, Paulsen MS, Zwisler JE, Farkas DK, Freiesleben Boldingh C, et al. Rapidly increasing prescribing of proton pump inhibitors in primary care despite interventions: a nationwide observational study. Eur J Gen Pract. 2014;20(4):290-3.
[35]. Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors: evidencebased clinical practice guideline. Can Fam Physician. 2017;63(5):354-64.
[36]. World Health Organization. VigiAccess: the WHO global database of reported potential side effects of medicinal products. Uppsala Monitoring Centre. Available from: http://www.vigiaccess.org/.
[37]. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A data mining approach for signal detection and analysis. Drug Saf. 2002;25(6):393-7. doi:10.2165/00002018-200225060-00002.
[38]. Medical Dictionary for Regulatory Activities (MedDRA). Introductory Guide MedDRA Version 24.0. International Council for Harmonisation; 2021.
[39]. Pal SN, Duncombe C, Falzon D, Bignadori S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75-81.
[40]. Meyboom RH, Egberts AC, Gribnau FW, Hekster YA. Pharmacovigilance in perspective. Drug Saf. 1999;21(6):429-47.
[41]. Kalaiselvan V, Srivastava S, Singh A, Gupta SK. Pharmacovigilance Program of India: present status and future perspectives. Pharmacogn Rev. 2019;13(25):1-4.
[42]. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743-52.
[43]. Uppsala Monitoring Centre. The use of the WHO global ICSR database, VigiBase, for academic research. Drug Saf. 2020;43(11):1105-15.
Pharmacovigilance; Pantoprazole; Omeprazole; Gastrointestinal symptoms; Adverse drug reactions; VigiAccess.
Note : A published paper may take 4-5 working days from the publication date to appear in Rode, Semantic Scholar, and open alex.
